A&D HOLON Holdings (7745) FY2027 Q1 Earnings Report

Quick View

Executive Summary

The most important point in this quarter’s results is that the sharp deterioration in profitability in the semiconductor-related business drove the decline in consolidated earnings. Revenue was ¥143.8B, nearly flat at -1.2% year on year, while Operating Income fell substantially to ¥6.2B, down 53.2%. Ordinary Income was ¥7.8B, down 45.3%, and quarterly Net Income attributable to owners of the parent was ¥4.3B, down 45.6%. The Operating Income margin declined significantly to 4.3% from approximately 9.1% in the same period of the previous year. Although increased revenue and earnings in the Medical and Healthcare Equipment Business provided support, this was offset by the semiconductor-related business falling into the red.

Factors Behind Performance Changes

【Revenue】Revenue was ¥143.8B, essentially flat at -1.2% year on year. The Medical and Healthcare Equipment Business grew significantly to ¥127.5B, up 26.2%, led by overseas operations, particularly the Americas at ¥31.0B and Europe at ¥23.4B. The Measuring and Weighing Instruments Business also increased revenue to ¥84.3B, up 6.1%, but the Semiconductor-Related Business declined sharply to ¥18.2B, approximately -68.9% from ¥28.9B in the previous year, offsetting the effect of revenue growth.

【Profit and Loss】Operating Income was ¥6.2B, down 53.2% year on year, while the Operating Income margin of 4.3% declined significantly from approximately 9.1% in the previous year. The Semiconductor-Related Business fell from segment profit of ¥10.0B in the previous year to a segment loss of ¥1.2B, representing the largest factor behind the decline in consolidated earnings. The Medical and Healthcare Equipment Business was the main earnings contributor, with segment profit of ¥11.3B, up 86.5%, accounting for more than 80% of total segment profit. Selling, general and administrative expenses of ¥59.0B absorbed most of Gross Profit of ¥65.2B, resulting in weak conversion from Gross Profit to Operating Income. Ordinary Income was ¥7.8B, ¥1.6B above Operating Income, due to non-operating income, including interest income of ¥1.8B. However, the combination of an extraordinary loss of ¥0.4B and a high tax burden with an effective tax rate of 40.8% limited Net Income to ¥4.4B. In conclusion, the Company recorded higher revenue but lower earnings.

Segment Analysis

The Semiconductor-Related Business recorded external revenue of ¥8.97B, approximately -68.9% year on year, while segment earnings fell from a profit of ¥10.0B in the previous year to a loss of ¥1.2B, making it the primary cause of the decline in consolidated earnings. The Measuring and Weighing Instruments Business improved, with external revenue of ¥67.8B, up 8.8%, and segment profit of ¥1.7B, up 203.6%; however, it incurred a ¥1.8B loss in the Americas, resulting in significant profitability disparities among regions. The Medical and Healthcare Equipment Business maintained high profitability, centered on Japan, where its profit margin was 21.4%, with external revenue of ¥67.1B, up 23.3%, and segment profit of ¥11.3B, up 86.5%, making it a core pillar of consolidated earnings. Adjustments, including corporate expenses, amounted to -¥5.6B and pressured consolidated Operating Income of ¥6.2B.

Key Financial Metrics

【Profitability】The Operating Income margin of 4.3% declined significantly from approximately 9.1% in the same period of the previous year, while the Net Income margin also contracted to 3.0% from approximately 5.5% in the previous year. The Gross Profit margin was maintained at 45.4%, but the SG&A expense ratio of 41.0% reduced profitability.【Cash Flow Quality】Working-capital turnover days, including DSO and DIO, have been trending upward. Accounts receivable of ¥150.5B and inventories of ¥119.8B together accounted for 36.4% of total assets, indicating a structure that requires time to convert assets into cash.【Investment Efficiency】ROE was 0.9% on a quarterly basis and remained approximately 3.5% on an annualized basis, indicating persistently low capital efficiency.【Financial Soundness】The Equity Ratio was 67.1%, while the Current Ratio was approximately 250%, based on current assets of ¥543.5B and current liabilities of ¥217.1B, indicating a conservative financial base. Meanwhile, short-term borrowings of ¥114.4B accounted for most interest-bearing debt, resulting in a funding structure heavily weighted toward short-term financing.

Cash Flow Analysis

Although the cash flow statement has not been disclosed, the Company’s cash position can be assessed from trends in the balance sheet. Cash and deposits increased to ¥146.4B from ¥137.6B in the same period of the previous year, indicating that ample liquidity has been maintained. Meanwhile, accounts receivable of ¥150.5B and inventories of ¥119.8B, comprising products of ¥119.8B, raw materials of ¥55.9B, and work in process of ¥49.2B, all remained at high levels. The increase in these working-capital items may be absorbing a portion of the funds generated from operating activities. Short-term borrowings increased to ¥114.4B from ¥104.5B in the previous year, suggesting that working-capital requirements are being supplemented through short-term borrowing. Long-term borrowings were limited at ¥1.3B, and interest-bearing debt was heavily concentrated in short-term obligations.

Quality of Earnings

Ordinary Income of ¥7.8B exceeded Operating Income of ¥6.2B by ¥1.6B because non-operating income of ¥2.5B, including interest income of ¥1.8B, exceeded non-operating expenses of ¥0.9B, including interest expenses of ¥0.7B. Interest income was approximately 1.3% of Revenue and supplements core business earnings as recurring income. Extraordinary income was ¥0.0B, compared with an extraordinary loss of ¥0.4B, including losses on disposal of fixed assets, representing a temporary factor that slightly reduced Profit Before Tax. The effective tax rate was high at approximately 40.8%, based on Profit Before Tax of ¥7.4B and income taxes of ¥3.0B, limiting the conversion to Net Income. Comprehensive Income was ¥11.0B, exceeding Net Income of ¥4.4B, primarily due to foreign currency translation adjustments of ¥6.7B. This divergence resulted from differences arising from the yen translation of overseas subsidiaries and has a different nature from recurring business earnings; this distinction should be noted.

Earnings Forecast and Guidance

The full-year Company forecast is Revenue of ¥680.0B, down 1.9% from the previous fiscal year; Operating Income of ¥70.0B, down 24.0%; and Ordinary Income of ¥69.0B, down 27.1%. No revisions had been made as of Q1. While the progress rate for Revenue was 21.2%, generally a standard level, the progress rates for Operating Income and Ordinary Income were only 8.9% and 11.4%, respectively, substantially below the 25% benchmark for even quarterly progress. Although the Company’s plan itself incorporates lower earnings year on year, profit progress as of Q1 is also behind the plan. Recovery in the Semiconductor-Related Business and control of SG&A expenses in the second half of the fiscal year will be key to achieving the plan.

Shareholder Returns

The full-year dividend forecast is ¥60.00 per share, representing an increase from the previous year’s annual dividend results, for which an interim-equivalent dividend of ¥25 was disclosed as of the same period of the previous year. No revision had been made to the dividend forecast as of Q1. Based on forecast full-year Net Income attributable to owners of the parent of ¥45.0B and the average number of shares outstanding during the period, the Payout Ratio is approximately 36.5%. The financial base, including cash and deposits of ¥146.4B and an Equity Ratio of 67.1%, supports the capacity to pay dividends. However, the Q1 progress rate for Net Income was only 9.6%, making achievement of the full-year earnings plan a prerequisite for securing the funds available for future dividends.

Risk Factors

1. Deterioration in profitability of the Semiconductor-Related Business: External revenue declined substantially year on year, and segment earnings fell from a profit in the previous year to a loss of ¥1.2B. The business structure is such that cyclical fluctuations in semiconductor capital investment and customer demand have a significant impact on consolidated performance.

2. Concentration of earnings in the Medical and Healthcare Equipment Business: This business accounts for more than 80% of total segment profit, and trends in demand and changes in the competitive environment overseas, particularly in the Americas and Europe, have a significant impact on consolidated earnings.

3. Working capital and short-term funding structure: Accounts receivable and inventories account for 36.4% of total assets and require time for cash collection, while most interest-bearing debt, ¥114.4B, consists of short-term borrowings. Although cash and deposits of ¥146.4B provide coverage, sensitivity to refinancing interest rates and changes in working-capital requirements is relatively high.

Industry Benchmark (For Reference; Compiled by the Company)

Industry Benchmark (manufacturing)

Profitability and Returns

Both the Operating Income margin and Net Income margin were below the industry median, indicating that profitability was relatively low within the industry.

Growth and Capital Efficiency

The Revenue growth rate was also substantially below the industry median, indicating that the Company was in a revenue-decline phase within an industry generally characterized by revenue growth.

※Source: Compiled by the Company

Key Points from the Financial Results

1. Although increased revenue and earnings in the Medical and Healthcare Equipment Business strengthened the earnings base, the Semiconductor-Related Business falling into the red drove a substantial decline in consolidated earnings, indicating high earnings volatility among businesses.

2. The Operating Income margin of 4.3% and progress rate of 8.9% against the full-year Operating Income plan were below the industry median and standard progress rate. The extent of recovery in the Semiconductor-Related Business during the second half of the fiscal year will be a key point to monitor in assessing achievement of the full-year plan.

3. While financial soundness was favorable, with an Equity Ratio of 67.1% and a Current Ratio of approximately 250%, the concentration of interest-bearing debt in short-term borrowings and the lengthening of working-capital turnover days require monitoring from a funding-efficiency perspective.

Theoretical Share Price (Reference Value)

Sensitivity: ¥1,768–¥1,871 at Cost of Equity ±1%, and ¥1,819–¥1,819 at ω±0.1.

Notes:

• Because forecast ROE is below the Cost of Equity, the theoretical value is below Book Value per Share.
• Net assets as of the end of the quarter are used; there is a timing difference relative to the full-year forecast.
• Because Net Assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; it is not a forecast of the market share price or a recommendation of any specific investment action, and does not forecast or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting with professionals as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2027 Q1 earnings were weak, with broadly flat revenue but a substantial contraction in operating and net profit. Revenue declined 1.2% YoY to ¥14.38bn. Operating income fell 53.2% YoY to ¥0.62bn, reducing the operating margin to 4.3% from 9.2% in the prior-year quarter, a compression of approximately 483bp. Net income attributable to owners declined 45.6% YoY to ¥0.43bn, and EPS was ¥15.80. Gross profit decreased only 1.0% YoY to ¥6.52bn, while gross margin was essentially stable at 45.4%, up roughly 6bp YoY. The main earnings pressure was therefore below gross profit, as SG&A increased 12.2% YoY to ¥5.90bn and its revenue ratio rose about 488bp to 41.0%. Medical and health equipment was the core business by segment-profit contribution, generating ¥1.13bn of segment profit on ¥6.71bn of external sales. Medical and health equipment revenue rose 23.3% YoY and segment profit rose 86.5%, showing strong demand particularly in Japan, the Americas and Europe. Measurement and weighing instruments also expanded revenue by 8.8% YoY to ¥6.78bn, although segment profitability remained low at ¥0.17bn. Semiconductor-related revenue fell 68.9% YoY to ¥0.90bn and the segment moved to a ¥0.12bn loss from a ¥1.00bn profit, representing the principal operational drag. Consolidated operating income was further constrained by unallocated corporate costs, which increased to ¥0.56bn from ¥0.47bn a year earlier. Ordinary income of ¥0.78bn benefited from ¥0.18bn of interest income, leaving earnings meaningfully supported by non-operating financial income rather than operations alone. The effective tax rate was elevated at 40.8%, reducing the conversion of pre-tax profit into net income. Comprehensive income nevertheless increased 7.0% YoY to ¥1.10bn, aided primarily by foreign currency translation gains. Against full-year guidance, Q1 revenue progress was 21.1%, modestly below the standard 25% pace, while operating-income progress was only 8.9% and net-income progress was 9.6%. The full-year earnings targets consequently require a pronounced recovery in semiconductor-related demand, improved measurement-equipment margins and tighter control of corporate and selling expenses over the remaining quarters.

Profitability Analysis

Annualized DuPont ROE is 3.5%, comprising a 3.0% net profit margin, 0.775x asset turnover and 1.49x financial leverage. The weak net margin is the principal constraint on returns, rather than excessive leverage, given the conservative 1.49x equity multiplier. Annualized asset turnover is moderate but does not compensate for the low earnings conversion. Operating margin fell to 4.3%, below the 5% efficiency threshold, from 9.2% a year earlier. This deterioration was driven by SG&A growth of 12.2% despite a 1.2% revenue decline, indicating negative operating leverage. Gross margin was stable at 45.4%, demonstrating that the consolidated margin shortfall was not principally caused by production cost inflation or pricing deterioration. Semiconductor-related operations shifted to a ¥0.12bn segment loss, compared with ¥1.00bn profit in the prior-year quarter, reflecting a sharp reduction in revenue and likely unfavorable fixed-cost absorption. In contrast, medical and health equipment achieved an approximately 16.9% segment-profit margin, versus approximately 11.2% a year earlier, making it the most profitable operating platform. Measurement and weighing equipment produced an approximately 2.5% segment-profit margin, improving from approximately 0.9% but remaining modest. The rise in corporate costs to ¥0.56bn reduced the extent to which strong medical-equipment performance translated into consolidated operating profit. The 5-factor analysis shows a tax burden of 0.581, below the 0.70 normal benchmark, while the interest burden exceeded 1.0 because interest income outweighed interest expense. Interest coverage of 8.41x remains sound. ROIC of 3.2% is below the 5% warning threshold, confirming that the current earnings base is not generating an adequate return on operating capital. The key requirement for a sustainable return recovery is a semiconductor profit normalization combined with SG&A discipline, rather than additional financial leverage.

Growth Assessment

Revenue performance was mixed across businesses. Medical and health equipment increased external sales by ¥1.27bn YoY to ¥6.71bn, led by the Americas, where sales rose ¥0.65bn, and Europe, where sales rose ¥0.44bn. Japanese medical and health equipment sales increased ¥0.15bn, while Asia-Oceania increased modestly by ¥0.03bn. Measurement and weighing equipment increased external sales by ¥0.55bn YoY to ¥6.78bn, with growth in Japan, the Americas, Europe and Asia-Oceania. These two businesses partly offset the ¥1.99bn YoY decline in semiconductor-related external sales. Semiconductor-related sales were concentrated in Japan, where sales fell from ¥2.89bn to ¥0.85bn, highlighting the business's cyclical sensitivity. The medical business's profit growth materially exceeded its sales growth, suggesting improved mix, operating leverage or pricing. Measurement and weighing profit also improved, but the absolute profit contribution remained limited. Consolidated revenue guidance of ¥68.00bn implies a 1.9% YoY decline for the full year. Q1 revenue progress of 21.1% is 3.9 percentage points below the standard 25% quarterly pace, but the shortfall is comparatively modest. Operating-income guidance of ¥7.00bn implies a 24.0% YoY decline, whereas Q1 progress of 8.9% is 16.1 percentage points below the standard pace. Ordinary-income progress is 11.4% against the ¥6.90bn full-year plan, also below the standard pace. The company has not revised its earnings forecast, so subsequent quarterly results need to demonstrate a recovery in the semiconductor business and a reversal of the Q1 SG&A burden.

Financial Health

Liquidity is strong, with a current ratio of 250.3% and a quick ratio of 195.1%. Current assets of ¥54.35bn exceed current liabilities of ¥21.71bn by ¥32.63bn. Cash and deposits of ¥14.64bn cover short-term loans of ¥11.44bn by 1.28x. Total interest-bearing debt is ¥11.57bn, equivalent to a conservative debt-to-equity ratio of 0.49x and debt-to-capital ratio of 18.8%. Total equity increased to ¥49.84bn from ¥49.58bn a year earlier, and the equity ratio is 67.0%. Solvency is therefore supported by a substantial equity buffer and modest aggregate leverage. However, 98.9% of interest-bearing debt is short term, creating refinancing risk even though near-term cash coverage is currently adequate. The reliance on short-term funding is notable because inventories and receivables represent a sizeable portion of current assets and may be less immediately liquid than cash. Accounts receivable were ¥15.05bn and finished-goods inventories were ¥11.98bn at quarter-end. Interest coverage of 8.41x provides a reasonable earnings cushion against current financing costs. Goodwill is only ¥0.14bn, or 0.3% of equity and 0.2% of assets, so balance-sheet dependence on acquired goodwill is immaterial. Intangible assets are 2.1% of total assets, also indicating limited intangible-asset concentration.

Notable B/S Changes

Accounts receivable: -¥4.03bn (-21.1% YoY) to ¥15.05bn - reduces the balance-sheet receivables balance, although annualized DSO remains elevated at 96 days. Work in process: +¥1.05bn (+27.2% YoY) to ¥4.92bn - indicates a larger amount of capital tied up in production and contributes to the extended inventory cycle. Finished goods: +¥0.83bn (+7.4% YoY) to ¥11.98bn - inventory increased despite a 1.2% revenue decline, increasing demand-forecasting and obsolescence sensitivity. Short-term loans: +¥0.99bn (+9.5% YoY) to ¥11.44bn - increases reliance on short-term funding, although cash and deposits of ¥14.64bn remain above this balance. Foreign currency translation adjustment: +¥0.67bn (+63.0% YoY) to ¥1.73bn - was the principal contributor to the increase in comprehensive income and equity translation reserves.

Cash Flow Quality

Dividend Sustainability

The full-year dividend forecast is ¥60 per share. Based on forecast EPS of ¥164.31, the implied dividend payout ratio is approximately 36.5%, below the 60% sustainability benchmark. This leaves a meaningful portion of forecast earnings available for reinvestment, debt management and balance-sheet resilience. Q1 EPS of ¥15.80 represents only 9.6% of full-year forecast EPS, so dividend coverage depends on management achieving a substantial earnings recovery over the remaining three quarters. The conservative balance-sheet leverage profile and cash balance provide support for the stated dividend plan. Maintaining the forecast dividend will nevertheless depend on recovery in operating earnings rather than continued reliance on non-operating interest income.

Risk Assessment

Business risks include Semiconductor cycle risk: semiconductor-related sales declined 68.9% YoY to ¥0.90bn and the segment shifted to a ¥0.12bn loss, making the timing of demand normalization a high-impact risk., Operating-leverage risk: SG&A increased 12.2% YoY while revenue declined 1.2%, causing a roughly 483bp operating-margin contraction to 4.3%., Working-capital risk: annualized DSO of 96 days exceeds the 60-day warning threshold, indicating slower cash collection and elevated customer-credit exposure., Inventory-management risk: finished-goods inventory of ¥11.98bn implies annualized inventory days of approximately 139 days, above the 60-day manufacturing benchmark., Broader production-inventory risk: raw materials of ¥5.59bn, work in process of ¥4.92bn and finished goods of ¥11.98bn indicate an extended operating inventory cycle; the quality alert's 261-day DIO measure and 314-day cash conversion cycle indicate capital tied up across production stages., Manufacturing-specific demand and supply-chain risk: semiconductor equipment demand is cyclical, while extended inventory holding periods increase exposure to product obsolescence, demand forecast error and margin pressure..

Financial risks include Refinancing risk: 98.9% of interest-bearing debt is short term. This maturity concentration is high relative to the 40% warning threshold, although cash covers short-term loans by 1.28x and the current ratio is 250.3%., Low capital efficiency: ROIC of 3.2% is below the 5% warning threshold, indicating that the present operating-profit base is not adequately monetizing invested capital., Tax-conversion risk: the 40.8% effective tax rate produces a tax burden of 0.581, below the 0.60 warning threshold and materially reduces net-income conversion., Non-operating-income dependence: interest income of ¥0.18bn represented 12.5% of revenue and exceeded interest expense of ¥0.07bn, supporting ordinary income despite weak operating income..

Key concerns include LOW_OPERATING_EFFICIENCY: EBIT margin of 4.3% is below 5%; the root cause is the combination of a semiconductor segment loss and SG&A growth materially exceeding revenue growth. The impact is depressed ROE and a demanding implied second-half recovery., HIGH_TAX_BURDEN: the 40.8% effective tax rate leaves only 58.1% of pre-tax profit as net income. While lower than the prior-year quarter's approximately 43.9% rate, it remains above the 40% alert level and limits earnings conversion., HIGH_RECEIVABLE_DAYS: annualized DSO of 96 days is well above the 60-day alert level. This reduces working-capital efficiency and could amplify cash-flow volatility if customer collections weaken., HIGH_INVENTORY_DAYS: finished-goods DIO of approximately 139 days is above the 60-day benchmark. The broader inventory-cycle indicator of 261 days is also elevated, reflecting raw materials and work in process in addition to finished goods; this heightens obsolescence and inventory-write-down risk., LONG_CCC: the 314-day cash conversion-cycle alert reflects the long collection and production inventory cycle relative to supplier financing. This creates a significant funding requirement even with strong reported current liquidity..

Investment Implications

Key takeaways include Stable gross margin indicates that Q1 weakness was primarily an operating-expense and business-mix issue rather than a broad deterioration in product-level profitability., Medical and health equipment is the principal profit engine, with segment profit of ¥1.13bn and an approximately 16.9% segment-profit margin., Semiconductor-related operations were the largest negative swing factor, moving from ¥1.00bn profit to a ¥0.12bn loss., Balance-sheet leverage is conservative, but the maturity profile is concentrated in short-term borrowings., The full-year operating-income forecast requires a material acceleration after Q1 progress of only 8.9%..

Metrics to watch include Semiconductor-related segment sales and return to segment profitability, Medical and health equipment margin durability, particularly in the Americas and Europe, SG&A growth relative to revenue growth and consolidated operating-margin recovery, Annualized DSO, finished-goods DIO and the broader cash conversion cycle, Short-term loan balance, cash-to-short-term-debt coverage and refinancing terms, Progress toward full-year revenue, operating income, ordinary income and EPS guidance.

Regarding relative positioning, The company combines a strong medical and health equipment profit platform with a currently loss-making semiconductor-related business and low-margin measurement operations. Its balance sheet is more conservatively levered than a highly debt-funded manufacturer, but its operating margin, ROIC and working-capital efficiency are currently below desirable manufacturing benchmarks.